Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-05-03 AGM Information
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 1% confidence The document explicitly announces the details for the 'Combined Shareholders' Meeting of 24 May 2022' and discusses the preparatory documents, agenda, and draft resolutions (including dividend approval and director renewals). This content is directly related to the formal proceedings and materials for an Annual General Meeting (AGM). Although it mentions the publication of notices, the core purpose of this specific document is to inform shareholders about the meeting itself and the documents available for it. This aligns perfectly with the AGM Information category (AGM-R). It is not a full 10-K, an earnings release, or a simple dividend notice, but a comprehensive notice regarding the AGM.
2022-05-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen, dated May 3, 2022, announcing that the European Commission (CE) has approved Cabometyx® for a specific indication (refractory differentiated thyroid cancer). The text details the basis for the approval (Phase III COSMIC-311 study results), includes quotes from medical professionals and company executives, and provides background information on the disease and the drug. This format—a formal announcement of a significant regulatory milestone or clinical data release—is characteristic of an Earnings Release (ER) or a general press release related to company performance/developments. Since it is a detailed announcement of a major regulatory event (drug approval) rather than just financial highlights (ER) or a transcript (CT), and it is not a formal statutory filing like a 10-K or IR, it best fits the category for a significant corporate announcement. Given the options, 'Earnings Release' (ER) is often used broadly for major corporate news announcements, but 'Regulatory Filings' (RNS) is the best fit for a general, non-financial, non-statutory regulatory update that doesn't fit other specific categories like DIRS or DIV. However, because this is a detailed announcement of a major regulatory approval based on clinical data, it functions similarly to an Earnings Release in terms of market impact and structure (press release format). Since it is not a financial results summary (ER) but a specific regulatory/clinical update, and it is not a short announcement pointing to an attached report (RPA), it falls under the general category of significant corporate news. Given the options, and recognizing this is a press release about a regulatory decision, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard, non-financial regulatory news, although 'ER' is sometimes used for major non-financial announcements. I will classify it as RNS as it is a regulatory announcement outside the core financial reporting cycle.
2022-05-03 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated May 3, 2022, announcing that the European Commission has approved Cabometyx® for a specific cancer treatment. It details the clinical trial data (COSMIC-311 Phase III) that supported this approval, discusses the medical significance, and provides background information on the disease and the drug. This content is characteristic of an official announcement regarding a significant regulatory milestone or clinical outcome, which is often released as an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on the immediate announcement of a major regulatory decision and provides key financial/clinical highlights rather than being a comprehensive annual report (10-K), interim report (IR), or a transcript (CT), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede quarterly results, or serve as major standalone news releases detailing significant corporate achievements like drug approvals. Given the context of a major drug approval announcement, ER is a strong fit, although RNS is a possibility if it were purely a regulatory filing notice. However, the structure strongly resembles a standard press release highlighting key results and corporate news, aligning best with ER.
2022-05-03 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Ipsen réalise une solide performance de ses ventes au premier trimestre 2022" (Ipsen achieves solid sales performance in the first quarter of 2022) and explicitly states it is publishing its revenue for the first quarter of 2022. It contains detailed financial tables comparing Q1 2022 results to Q1 2021, discusses product performance, confirms financial objectives for the full year 2022, and mentions the next reporting date (H1 2022 results on July 28, 2022). This structure—a press release detailing financial results for a period shorter than a year—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it provides the initial announcement of the period's financial results (Q1 2022 sales) with key highlights and commentary, it fits the definition of an Earnings Release (ER). It is not the comprehensive, audited report (10-K or IR), but the initial release. Q1 2022
2022-04-27 French
Franchissement de seuil
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing a threshold (Article L. 233-7 of the Commercial Code)'. This type of filing in France (AMF regulated) specifically reports when an investor's stake crosses a significant ownership threshold (like 5%). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant share ownership levels crossing thresholds. The code for this is MRQ.
2022-04-21 French
Annual financial and audit reports / Terms of availability of the annual financial report
Report Publication Announcement Classification · 1% confidence The document explicitly announces that Ipsen 'publishes its 2021 Universal Registration Document' and states that this document 'has been filed with the French Autorité des Marchés Financiers'. A Universal Registration Document (URD) in the European context is a comprehensive annual filing that often incorporates the Annual Financial Report and Corporate Governance details, similar in scope to a US 10-K, but it is being announced here as a publication event. The text is short (6346 chars) and focuses on the availability of the document rather than containing the full financial statements or management discussion itself. According to Rule 2, when a document announces the publication of a major report, it should be classified as a Report Publication Announcement (RPA). While the URD contains elements of an Annual Report (10-K), the nature of this specific text is the announcement of its release.
2022-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.